OBJECTIVE: To compare neurocognition and quality-of-life (QoL) in a group of children and adolescents with or without growth hormone deficiency (GHD) following moderate-to-severe traumatic brain injury (TBI). STUDY DESIGNS: Thirty-two children and adolescents were recruited from the TBI clinic at a children's hospital. Growth hormone (GH) was measured by both spontaneous overnight testing and following arginine/glucagon stimulation administration. Twenty-nine subjects participated in extensive neuropsychological assessment. RESULTS: GHD as measured on overnight testing was significantly associated with a variety of neurocognitive and QoL measures. Specifically, subjects with GHD had significantly (p < 0.05) lower scores on measures of visual memory and health-related quality-of-life. These scores were not explained by severity of injury or IQ (p > 0.05). GHD noted in response to provocative testing was not associated with any neurocognitive or QoL measures. CONCLUSIONS: GHD following TBI is common in children and adolescents. Deficits in neurocognition and QoL impact recovery after TBI. It is important to assess potential neurocognitive and QoL changes that may occur as a result of GHD. It is also important to consider the potential added benefit of overnight GH testing as compared to stimulation testing in predicting changes in neurocognition or QoL.
OBJECTIVE: To compare neurocognition and quality-of-life (QoL) in a group of children and adolescents with or without growth hormone deficiency (GHD) following moderate-to-severe traumatic brain injury (TBI). STUDY DESIGNS: Thirty-two children and adolescents were recruited from the TBI clinic at a children's hospital. Growth hormone (GH) was measured by both spontaneous overnight testing and following arginine/glucagon stimulation administration. Twenty-nine subjects participated in extensive neuropsychological assessment. RESULTS: GHD as measured on overnight testing was significantly associated with a variety of neurocognitive and QoL measures. Specifically, subjects with GHD had significantly (p < 0.05) lower scores on measures of visual memory and health-related quality-of-life. These scores were not explained by severity of injury or IQ (p > 0.05). GHD noted in response to provocative testing was not associated with any neurocognitive or QoL measures. CONCLUSIONS: GHD following TBI is common in children and adolescents. Deficits in neurocognition and QoL impact recovery after TBI. It is important to assess potential neurocognitive and QoL changes that may occur as a result of GHD. It is also important to consider the potential added benefit of overnight GH testing as compared to stimulation testing in predicting changes in neurocognition or QoL.
Authors: Lucia I Arwert; Dick J Veltman; Jan Berend Deijen; P Sytze van Dam; Henriette A Delemarre-van deWaal; Madeleine L Drent Journal: Neuroendocrinology Date: 2005-12-05 Impact factor: 4.914
Authors: I Kreitschmann-Andermahr; E M Poll; A Reineke; J M Gilsbach; G Brabant; M Buchfelder; W Fassbender; M Faust; P H Kann; H Wallaschofski Journal: Growth Horm IGF Res Date: 2008-10-01 Impact factor: 2.372
Authors: H B Baum; L Katznelson; J C Sherman; B M Biller; D L Hayden; D A Schoenfeld; K E Cannistraro; A Klibanski Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: Juan David Olivares-Hernández; Jerusa Elienai Balderas-Márquez; Martha Carranza; Maricela Luna; Carlos G Martínez-Moreno; Carlos Arámburo Journal: Neural Plast Date: 2021-09-16 Impact factor: 3.599